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ABSTRACT 
Bone resorption is dependent on the differentiation of osteoclast progenitor cells 
into mature osteoclasts. The roles of receptor activator of NF -K8 ligand (RANKL), the 
decoy receptor for RANKL (osteoprotegerin, OPG) and macrophage-colony stimulating 
factor (M-CSF), which are produced by osteoblasts or stromal cells, in 
osteoclastogenesis are well established. RANKL and M-CSF are both considered to be 
essential for osteoclastogenesis, while OPG is an inhibitor of RANKL actions. Tumor 
necrosis factor (TNF-a) is a potent stimulator of bone resorption, especially under 
inflammatory conditions. However, the role of TNF-a in osteoclast proliferation, 
differentiation and activation is still unclear. It has been reported previously that TNF-a 
stimulates bone resorption indirectly via a primary effect on osteoblasts to increase 
RANKL or decrease OPG. On the other hand, TNF- a has also been proposed to have 
a direct action on the proliferation and differentiation of osteoclast progenitors [1]. 
In our current research, we use RA W 264.7 cells, a cell line of monocyte-
macrophage lineage. RAW 264.7 cells make M-CSF but do not express RANKL. 
They can develop into osteoclasts if given RANKL. Our hypothesis is that TNF-a 
cannot stimulate osteoclastogenesis without RANKL in RAW 264.7 cells but can 
enhance the effects of RANKL on osteoclastogenesis via the induction of 
cyclooxygenase-2 (COX-2) and production of prostaglandins. 
The aims of this study are to determine ifTNF-a can stimulate osteoclastogenesis in 
RA W 264.7 cells in the absence of RANKL and if TNF -a enhances the effect of added 
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RANKL in this system VIa the TNF-a induction of prostaglandins produced by 
cyclooxygenase (COX-2). 
This project will help determine the role of TNF-a in osteoclast formation. This 
will give us a better understanding of the processes involved in bone remodeling in 
orthodontic tooth movement as well as in several diseases such as rheumatoid arthritis 
and periodontitis. 
3 
INTRODUCTION 
Objective of Research 
Previous research has shown that pro inflammatory cytokines, such as TNF-a and 
interleukin-l (IL-l), playa role in the biologic processes involved in orthodontic tooth 
movement. The inhibition of cytokine activity by the addition of soluble receptors 
reduced the amount of tooth movement by 50% and also reduced the number of 
osteoclasts [2]. 
Prostaglandins (PGs) are potent stimulators of bone resorption and are produced 
largely by the induction of COX-2 in osteoblasts [21]. The effect of prostaglandins on 
tooth movement has been studied extensively. Yamasaki et al [3] suggested that 
orthodontic mechanical stress induced synthesis and secretion of prostaglandins (PGs) 
by localized cells, which stimulated osteoclastic bone resorption. When PGEl or PGE2 
were injected in the gingiva near the upper first molar in rats, osteoclasts and alveolar 
bone resorption were observed. On the other hand, the administration of indomethacin, 
an inhibitor ofPG production by both COX-l and COX-2, suppressed the appearance of 
osteoclasts and bone resorption. Davidovitch et al [4] reported the involvement ofPGE2 
in bone remodeling in orthodontically treated cats. Guinta et al [5] treated miniature 
pigs with indomethacin and showed a significant decrease in the extent of resorption 
surfaces histologically. 
Cytokines, such as TNF-a and IL-l, have been shown to induce COX-2 expression 
and PG production in osteoblasts and in cultured bone marrow cells [21] [6]. These 
cytokines are potent inducers of bone resorption, and some of their effects on resorption 
may be mediated via their induction of COX-2 and PGs [21]. Most of the regulation of 
4 
osteoclastogenesis by cytokines and PGs is thought to occur via the induction of 
RANKL in osteoblasts, which then binds to RANK receptor on cells of the 
hematopoietic lineage. However, it has been proposed that TNF-(l can induce 
osteoclastogenesis by acting directly on cells of the hematopoietic lineage, 
independently of RANKL. Therefore, the objective of this research is to determine if 
TNF-(l can stimulate osteoclast formation via induction of COX-2 in cells of the 
hematopoietic lineage. 
Background 
Osteoclasts 
Osteoclasts are multinucleated giant cells that resorb bone. They develop from the 
hemopoietic cells of the monocyte-macrophage lineage. Major characteristics of 
osteoclasts are (1) Tartarate-resistance acid phosphatase (TRAP) activity, (2) expression 
of calcitonin receptors (CTR), (3) multinucleation, and (4) ability to resorb mineralized 
bone. TRAP is a resorptive enzyme identified in both the ruftled border of the 
osteoclast membrane and the secretions in the resorptive space [7]. 
Osteoblasts/stromal cells are crucially involved in osteoclast development. Cell-to-
cell contact between osteoblasts/stromal cells and osteoclast progenitors is necessary for 
induction of osteoclast differentiaton.[8] Osteoclast differentiation involves several 
major stages outlined in Figure 1. 
Osteoclasts arise from hematopoietic stem cells (HSCs). HSCs give rise to colony 
forming unit-granulocyte/macrophages (CFU-GMs). Macrophage/monocyte-colony 
stimulating factor (M-CSF) stimulates the proliferation of CFU-GMs (osteoclast 
precursors), which lack two osteoclast markers: TRAP and CTR. The mononuclear 
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precursors differentiate into prefusion osteoclasts (positive for both TRAP and CTR) 
with the stimulation of M-CSF and RANKL. The prefusion osteoclasts will further 
differentiate by fusion to become multinucleated cells (with continuous stimulation of 
M-CSF and RANKL). When these multinucleated cells become functional, they have a 
ruffled border [9]. RANKL continues to play an important role in activating osteoclasts 
by stimulating formation of the ruffled membrane [10]. 
RA W 264. 7 Cells 
There is only one known clonal cell line that can give rise to osteoclasts in vitro. 
The RAW 264.7 cell line is a functional macrophage cell line transformed by the 
Abelson Leukemia Virus. These cells produce cytokines in response to lipopoly-
saccharide (LPS) and can make osteoclasts in response to RANKL [11-13]. Since they 
produce M-CSF, it is not necessary to add M-CSF to cultures. 
RANKL, M-CSF and Osteoprotegerin 
RANKL is the ligand for the receptor activator of NF-KB. It is also called 
osteoprotegerin ligand (OPGL) [8]. It is a member of the TNF superfamily. It is a cell 
surface molecule expressed by marrow stromal cells and osteoblasts, and by activated T 
lymphocytes [14]. It is involved in bone metabolism by mediating osteoclast 
differentiation, function and survival [11]. The discovery of RANKL helped establish 
that osteoblasts/stromal cells support osteoclast differentiation primarily by serving as a 
source of RANKL as well as M-CSF [10). Osteoblast/stromal cells express both M-
CSF and RANKL (membrane-bound and soluble), which bind to their respective 
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receptors, c-fms and RANK, expressed on osteoclast precursors to stimulate osteoclast 
formation. In vitro, M-CSF and RANKL have been shown to be sufficient for 
osteoclastogenesis [15]. Both RANKL knockout and RANK knockout mice show 
features of osteopetrosis with a complete absence of osteoclasts in bone[16]. 
Osteoblasts/stromal cells also produce osteoprotegerin (OPG), a soluble decoy 
receptor for RANKL. OPG inhibits RANKL function by competing with RANK for 
RANKL [9]. 
TNF-a 
TNF-a also modulates osteoclast formation and function [17]. TNF-a exerts its 
function via two receptors. TNF-a receptor 1 (TNFR1), or p55, contains a death 
domain (DD), and the binding of TNF -a to TNFRI triggers programmed cell death 
[18]. TNFR2, or p75, lacks a DD [9]. TNF-a signal pathways stimulate bone 
resorption as well as inhibit bone formation. Binding ofTNF-a to its receptor activates 
TNF-a receptor-associated death domain (TRADD), which in turn stimulates two well 
known pathways: (1) activation of nuclear factor kappa B (NF-KB), Jun kinase (JNK), 
p38 kinase, protein kinase C (PKC), and (2) activation of Fas activated death domain 
(F ADD), a protein that triggers the pro-apoptotic caspases and cell death. These 
pathways are not mutually exclusive, which makes the study if TNF -a action difficult 
[17]. 
Unlike mice lacking RANKL or RANK, mice lacking TNF-a or its receptor do not 
exhibit any bone defects [19], indicating that lNF-a mediated signaling is not essential 
for skeletal development and physiologic bone remodeling. Inflammatory cytokines 
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like TNF-a: and IL-l are secreted by macrophages and lor T-cells during pathologic 
bone resorption, for example, in rheumatoid arthritis, periodontitis, and loosening of 
implants [20]. 
Prostaglandins (PGs) and Cyclooxygenase-2 (COX-2) 
Conversion of arachidonic acid (AA)--a 20 carbon fatty acid derived from the 
cellular lipid bilayer--by cyclooxygenase (COX or prostaglandin endoperoxide 
synthase) is the committed step in PG synthesis [21] (Figure 2). PGs are eicosanoids 
produced by COX and exhibit numerous functions throughout the body. 
There are two isoforms of COX, COX-l and COX-2, which have significant 
sequence homology and identical catalytic activity, but their expression pattern is 
markedly different. They have significant differences in mRNA splicing, stability and 
translational efficiency, and they use different substrate pools [6]. The COX enzymes 
are associated with two types of receptors: G-protein coupled receptors (transmembrane 
receptors), and peroxisome proliferators-activated receptors (PPARs), which are 
members of the nuclear receptor family of transcription factors. The most abundant PG 
produced by osteoblasts, PGE2, is associated with four classes of receptors, EPI-EP4, 
which are G-protein coupled receptors [21]. 
COX-l and COX-2 are produced throughout the human body. COX-l is 
constitutively expressed in nearly all tissues (including osteoblasts) while COX-2 is 
inducible. It was hypothesized that COX-2 is responsible for acute PG responses 
associated with inflammation and pain, while COX-1 produces those prostanoids 
needed for ongoing "housekeeping" functions, including maintenance of renal blood 
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flow, platelet aggregation, and gastric cytoprotection. COX-2 is produced in response 
to IL-1, TNF-a, TGF-a, TGF-~, parathyroid hormone, 1,25(OH)2D3 and mechanical 
loading of bone [21]. The induction of COX-2 is transient, with a return to base-line 
within 24-48 hours [6]. 
Non-selective, non-steroidal anti-inflammatory drugs (NSAIDs), such as 
indomethacin, inhibit PG production by competing directly with AA for binding to the 
cyclooxygenase catalytic site. Therefore, they are used to study the role of endogenous 
PGs. NS-398 is a selective NSAID that inhibits COX-2 activity at a concentration of 
0.01 JlM, but loses its selectivity at higher doses [21]. 
PGs appear to have a dual role in bone remodeling by enhancing both osteoclast 
and osteoblast formation. Although PGs are known to be potent mediators of bone 
resorption, their actions are complex. Osteoclastogenesis is enhanced because of an 
increase in RANKL production. Induction of RANKL has been shown to be essential 
for resorption by PGE2 [22], but PGE2 may also have some stimulatory effects on the 
hematopoietic lineage as well [21]. On the other hand, PGE2 has also been shown to 
inhibit the activity of mature osteoclasts [21]. Han et al [23] have shown that RANKL 
can induce COX-2 expression, which results in production of PGE2 in RAW 264.7 
cells. PGs also seem to increase osteoblast formation by recruiting osteoblast precursors 
from a population of non adherent mesenchymal precursors in the bone marrow [24]. 
Thus, PGs can stimulate both resorption and formation and the balance of these 
activities in vivo may determine whether bone is gained or lost. 
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TNF-a and Osteoclastogenesis 
In bone metabolism, it has been shown that numerous TNF family members 
including RANKL, TNF-a, Fas ligand (FasL) and TNF-related apoptosis-inducing 
ligand (TRAIL) play pivotal roles in the differentiation, function, survival and/or 
apoptosis of osteoclasts [9]. TNF-a can induce RANKL production by osteoblasts or 
marrow stromal cells and promote osteoclastogenesis. There is also the possibility that 
ll\JF-a can induce osteoclastogenesis independent of RANKL by acting directly on 
cells of the hematopoietic lineage. 
Lam et al [14] showed that TNF-a targets both marrow stromal cells and 
hematopoietic osteoclast precursors, but directly impacts the latter only in the presence 
of permissive levels of RANKL. A pure population of murine osteoclast precursors 
failed to undergo osteoclastogenesis when treated with TNF-a. However, TNF-a 
dramatically stimulated differentiation in macrophages primed by less than 1 % of the 
amount of RANKL required to induce osteoclast formation. Administration of TNF-a 
to RANK deficient animals failed to induce osteoclastogenesis, indicating that TNF-a 
could not substitute for RANKL in physiological conditions. Macrophages isolated 
from marrow cultures when treated with OPG were incapable of TNF-a induced 
osteoclastogenesis. TNF-a potentiation of RANKL-primed osteoclastogenesis was 
time-sensitive. TNF-a added concomitantly with the priming dose of RANKL failed to 
induce osteoclast formation. In contrast, when TNF-a was added 2-4 days after 
RANKL priming, TNF -a induced osteoclastogenesis was maxima1. Outside of this 
temporal window, TNF -a appeared to drive macrophage development along a 
nonosteoclastogenic pathway. 
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Zou et al [25] showed that TNF -u expression can be transcriptionally regulated by 
RANKL. RANKL increased TNF-u expression by 8-fold and 4.5-fold in RAW 264.7 
and bone marrow macrophages (BMMs), respectively. RANKL increased TNF-u 
transcription rate by 2.9-fold in RAW 264.7 cells. This transcriptional mechanism was 
dependent on the NF-K8 sites in the TNF-u promoter. Hence, it is possible that some of 
the effects ofRANKL might be mediated by RANKL-induced TNF-u. 
Wei et al [26] found that TNF -u exerts its osteoclastogenic effect Via IL-l-
dependent and -independent signaling pathways and that the IL-l-mediated effect 
involves, at least in part, RANKL-producing stromal cells. IL-l alone was incapable of 
promoting osteoclast formation in macrophage/stromal cell coculture. However, IL-l 
also directly targeted osteoclast precursors and promoted the osteoclast phenotype in a 
TNF-independent manner in the presence of permissive levels ofRANKL (Figure 3). 
On the other hand, Kobayashi et al [18] demonstrated that TNF-u can stimulate 
osteoclast differentiation in the presence of M-CSF through a mechanism independent 
of the RANKL-RANK interaction. They used bone marrow cells cultured for 3 days, 
after which M-CSF dependent bone marrow macrophages (M-BMMs) were isolated 
and treated with TNF -u. Osteoclast formation induced by TNF -u was inhibited by the 
addition of antibodies against TNFRI (no TRAP-positive cells) or TNFR2 (markedly 
reduced TRAP positive cells), but not by osteoprotegerin (OPG, a decoy receptor for 
RANKL), nor the Fab fragment of anti-RANK antibody. Real time-polymerase chain 
reaction (RT-PCR) showed that M-BMM expressed RANKL mRNA, but its levels were 
low and not upregulated by adding TNF -u. 
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Azuma et al [IJ using a cell culture similar to that used by Kobayashi et al [18], 
found that TNF -a was a crucial differentiation factor for osteoclasts in the presence of 
M-CSF, via the p55 TNF receptor. TNF-a directly induced the formation of TRAP-
positive multinucleated cells (MNCs) in a dose-dependent manner at TNF-a 
concentrations of 10 ng/ml and above. The number of TRAP-positive MNCs in TNF-a-
treated groups was about 50% of that in the soluble RANKL-treated groups. The bone 
resorption activity of TNF-a induced NINCs was also lower than that of the RANKL-
induced MNCs. 
Zou et al [27] used cell cultures derived from three different mouse strains, Balb/c 
and C57BLl6 (strains known to differ in inflammatory responses and cytokine 
modulation) as well as RAW 264.7 cells. In the Balb/c cells, the following results were 
seen: 
1. TNF -a enhanced osteoclastogenesis in co-culture and in RANKL treated bone 
marrow cells. Antibodies to TNF -a and ll\lFRI inhibited RANKL induction of 
osteoclastogenesis (also seen in RAW 264.7 cells). 
2. TNF-a alone promoted osteoclastogenesis in the presence ofM-CSF (but was less 
efficient than RANKL). 
3. RANKL increased abundance of TNF-a mRNA and induced secretion of the 
TNF-a (also seen in RAW 264.7 cells). 
4. OPG inhibited RANKL induced osteoclastogenesis and TNF-a expression, but 
not TNF-a activity. 
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In the C57BLl6 cells, TNFR-1 antibodies did not affect RANKL-induced 
osteoclastogenesis. Therefore, the authors concluded that there were different modes of 
action ofRANKL in the two strains. 
Hsu et al [11] showed that the RAW 264.7 cell line expressed high levels of RANK 
mRNA. Treatment of RAW 264.7 cells with murine RANKL readily stimulated cell 
differentiation into osteoclast-like TRAP-positive cells. They also showed that RANKL 
induced JNK activation in RAW 264.7 cells. Activation of JNK was readily detectable 
after 5 minutes ofRANKL exposure. NF-KB activation was not detectable in RANKL-
treated RAW 264.7 cells. These data, strongly suggest lun kinase as a potentially 
important osteoc1astogenic signal transducer. 
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RESEARCH PLAN 
Rationale 
For tooth movement to occur, bone resorption has to occur on the compression side 
and bone deposition on the tension side. Therefore, osteoclasts and osteoblasts play an 
active role in tooth movement. Under physiologic conditions, osteoblasts secrete 
RANKL, which helps maintain function, but they do not express IL-l or TNF -0:. 
However, under pathologic conditions or under the loading conditions necessary for 
orthodontic tooth movement, these cytokines can be expressed. Since they are potent 
stimulators of PG formation and bone resorption, they may contribute to the resorption 
that permits tooth movement [28]. This goal of this project is to examine the role of 
TNF-o: in the formation of bone resorbing cells. 
Preliminary Data 
Preliminary experiments were done in our lab on RAW 264.7 cells. The effects of 
TNF-a and PGE2 on RAW 264.7 cells treated with RANKL (30 ng/ml) were observed. 
The number of osteoclasts increased significantly when treated with TNF -0: or PGE2. 
The effect of TNF -0: was dose-dependent (Figure 4). 
A second experiment was conducted to see the effect of a COX-2 inhibitor (NS-
398) on RAW 264.7 cells treated with PGE2 + RANKL and TNF-o: + RANKL. There 
was a significant reduction in the number of TRAP-positive cells with the addition of 
NS-398 (Figure 5). 
To take this one step further, we decided to determine if TNF-o: alone can stimulate 
osteoclast formation. Previous literature has shown that it may [1, 18, 27]. However, 
these experiments were done in bone marrow macrophages cultured with whole marrow 
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cells for three days before they were isolated. Therefore these cells had been exposed to 
RANKL prior to treatment with TNF-a. According to Lam et al [14], this priming with 
RANKL is crucial for osteoclastogenesis with TNF-a. We propose the use of the RAW 
264.7 cell line, which is a macrophage cell line that does produce RANKL and therefore 
has no exposure to RANKL unless it is added. 
This preliminary data and a review of the current literature led us to our current 
hypothesis. 
Hypothesis 
1. ThTF -a cannot stimulate osteoclastogenesis by itself in RAW 264.7 cells but can 
stimulate osteoclastogenesis in the presence of RANKL. 
2. TNF-a can enhance the RANKL stimulated osteoclastogenesis by increasing COX-
2 expression and PG production in RAW 264.7 cells. 
Specific Aims 
Aim 1. To determine ifTNF-a alone can stimulate osteoclastogenesis in RAW 264.7 
cells. 
Aim 2. To determine ifTNF-a enhances RANKL induced osteoclastogenesis 
Aim 3. To determine ifTNF-a induces COX-2 expression and PG production in RAW 
264.7 cells 
Aim 4. To determine the effect of inhibiting PG production by indomethacin (a general 
inhibitor of both COX-l and COX-2 activity) and NS-398 (a selective inhibitor of 
COX-2 activity) on TNF-a induced osteoclastogenesis. 
Materials and Methods 
Materials 
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Tl~F-(l was obtained from Roche Diagnostics (Indianapolis, IN). RANKL was 
from R&D Biosystems (Minneapolis, MN). NS-398 was from Cayman Chemical 
Company (Ann Arbor, MI). Culture media were purchased from Gibco-BRL (Grand 
Island, NY). All other reagents were purchased from Sigma (St. Louis, MO) unless 
otherwise specified. 
Cell Culture 
We used the RAW 264.7 murine macrophage cell line. Cells were plated at 
concentrations of 1.2x104 cells/well or 6xl04 cells/well in 12 well dishes in (l-MEM 
with 10% heat activated fetal calf serum (HIFCS), 100 V/ml of penicillin and 50 Jlg/ml 
of streptomycin and cultured in a humidified atmosphere of 5% C02 at 37°c. We 
started with an initial cell concentration of 6x 104 cells/well, but due to the large number 
of osteoclasts produced, quantification was difficult and we reduced the concentration 
to 1.2x104 cells/well. Cells were treated with RANKL (30 ng/ml), lliF-(l (10 ng/ml) 
and RANKL + ThTF-(l. The vehicle was phosphate buffered saline (PBS) with 0.1 % 
bovine serum albumin (BSA). Media were changed on day 2. 
To inhibit COX-2 activity, cells were treated with indomethacin (1 J1M) or NS-
398 (0.1 J1M) and the vehicle, 0.1 % ethanol, was added to control cultures. 
Tatrate Resistance Acid Phospatase Staining 
Cells were fixed at the end of culture with 2.5% glutaraldehyde. A Leukocyte 
Acid Phosphatase Kit (Sigma) was used to stain for tartrate resistant acid phospahatase 
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(TRAP, a marker of osteoclasts) following the manufacturer's instructions. The TRAP 
positive multinucleated cells (MNCs), with 3 or more nuclei, were counted under the 
microscope at lOX magnification. Media were collected from each well, placed in 
dishes covered with parafilm securely and stored at -20°C for PGE2 assays. 
PGE2 Assay 
Medium was removed from cultured cells and PGE2 accumulation was 
measured on days 2, 3 and 4 using enzyme immunoassay kits. The experiment was 
repeated three times with three different enzyme immunoassay kits following the 
manufacturer's instructions: (1) EIA Cayman (monoclonal), Ann Arbor, MI. The 
detection range was 7.8-1000 pg/mL (2) Cayman Express, Ann Arbor, MI. The 
detection range was 15.6 pg/ml to 2000 pg/mL (3) Assay Designs, Ann Arbor, MI. The 
detection range was 38.7 pg/ml to 2600 pg/ml (0.11 to 7.4 nM). 
RNA Extraction, Real Time-PeR 
Cells were plated in 12-well dishes at a concentration of 1.2xl04 cells/well and 
treated with vehicle, RANKL (30 ng/ml), TNF-a (10 ng/ml) or RANKL + TNF-a. 
Three wells of cells were pooled for one sample. Total RNA was extracted using Trizol 
(Invitrogen, Carlsbad, California) in accordance with the manufacturer's directions. 2-5 
I!g of total RNA was converted to cDNA by the High Capacity cDNA Archive Kit 
(Applied Biosystems, Foster City, CA) following manufacturer's instructions. 
Quantitative PCR for gene expression was performed in 96-well plates using Assays-
on-Demand Gene Expression system (Applied Biosystems). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) served as the endogenous control. Each sample 
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was amplified in duplicate. Primers were tested for equal efficiency over a range of 
target gene concentrations. The PCR reaction mixture (20 JlL/well including 2X 
TaqMan Universal PCR Master Mix, 20X Assays-on-Demand Gene Expression Assay 
Mix and 40 ng of cDNA) was run in Applied Biosystems ABI Prism 7300 Sequence 
Detection System instrument utilizing universal thermal cycling parameters. A pool of 
reversed transcribed samples was the calibrator. We used the relative standard curve 
method, which sets standard curves for the target gene and endogenous control 
(GAPDH) by serially diluting total RNA, normalizes the amount of the target gene 
calculated from the standard curve to the amount of the control gene calculated from the 
standard curve, and compares the fold induction to the calibrator sample. 
Statistical Analysis 
All values are depicted as the mean ± standard error of the mean (SEM). 
Statistical analysis was performed using SigmaStat® for Microsoft Windows®, version 
2.03 (San Rafael, CA). To compare multiple treatment groups, differences were 
examined by one-way analysis of variance (ANOV A) followed by the post hoc 
Bonferroni's test. 
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RESULTS 
SPECIFIC AIM #1: To determine if TNF-a alone can stimulate osteoclustogenesis in 
RA W 264.7 cells 
No osteoclasts were observed in the control cultures. In the wells treated with 
TNF -a alone, there appeared to be an increase in the number of TRAP stained 
mononuclear cells on day 3 of the culture as compared to the control. The mononuclear 
cells also appeared to aggregate to form clusters. Osteoclast formation, defmed as 
TRAP positive MNCs, began on day 4. The microscopic images of the wells showed 
large, MNCs (2: 3 nuclei) that were stained purple due to TRAP activity (Figures 6 and 
7). This experiment was repeated five times. In three of the experiments, the peak in 
TNF -a induced osteoclast formation was on day 4 (Figures 8 and 9). In the remaining 
two experiments, the peak in the number of osteoclasts was observed on day 5 (Figure 
10). There was a large variation in the number of TNF-a induced osteoclasts in the 
different experiments. For example, in one experiment, there were 189 ± 5 osteoclasts 
on day 4 and 462 ± 33 osteoclasts on day 5 (Figure 10, expt 5). In another experiment, 
there were 7 osteoclasts on day 4 and 1.5 ± 0.5 on day 5 (Figure 9). The reason for this 
variability is unclear. There are several possibilities: 1) changes in the phenotype with 
the passage of the cells, 2) unintended differences in the plating densities, and 3) 
decreased efficacy of the TNF-a stock over time. 
SPECIFIC AIM #2: To determine if TNF-a can enhance RANKL induced 
osteoclastogenesis 
When the RAW 264.7 cells were treated with RANKL + TNF-a, there was a 
statistically significant increase in the number of osteoclasts on day 3 (p<0.05) and on 
day 4 (p<0.01) as compared to RANKL alone (Figures 7 and 11). This experiment was 
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repeated 4 times with similar results. On day 5, there was a decrease in the number of 
osteoclasts with RANKL + TNF -a as compared to RANKL alone. However, this 
difference was not statistically significant. Examination of the wells on day 5 showed 
the appearance of ghost cells, which lacked the TRAP positive staining as well as an 
intact cell membrane (Figure 7). 
SPECIFIC AIM #3: To determine if TNF-a induces COX-2 expression and 
prostaglandin production in RA W 264.7 cells 
Media from the cell culture experiments were analyzed for PGE2 production via 
Enzyme Immunoassay (EIA). The experiment was repeated three times with three 
different assay kits. There was an n=l in each treatment group. 
1. Cayman EIA (7.8 1000 pg/ml): The PGE2 levels were below the detection 
range in the control cultures. Treatment with TNF-a increased PGE2 
accumulation in the media (the values ranged from 17.8 to 78.6 pg/ml). (Table 
1). 
2. Cayman Express (15.6 - 2000 pg/ml): The PGE2 levels were below the 
detection range on days 2 and 4 of the control cultures. On day 3, PGE2 level 
was measured at 20.9 pg/ml, which is barely detectable. Treatment with TNF-a 
increased PGE2 accumulation in the media by 5-fold (105.7 pg/ml) or more as 
compared to the control (Table 2). 
3. Assay Design ErA kit (detection range 38.7 2600 pg/ml): The PGE2 levels 
were below the detection range in the control cultures. Treatment with TNF-a 
increased PGE2 accumulation in the media and the values ranged from 77.85 to 
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439.6 pg/ml (the assay was repeated twice on each sample and the given values 
are a mean of the two readings) (Table 3). 
There was a consistent trend in all three assays of increasing PGE2 levels from day 2 
through day 4 when treated with TNF -a. These assays were also performed on media 
from cells treated with TNF-a + indomethacin. Levels of PGE2 in the media from 
indomethacin treated cells were below the detectable range. 
Real time PCR conducted on day 3 showed a small induction of COX-2 mRNA 
when RAW 264.7 cells were treated with TNF-a (10 ng/ml). This increase in COX-2 
expression was statistically significant (p<O.Ol) (Figure 12). However, since COX-2 is a 
transiently expressed gene, we may have missed a larger induction earlier in culture. 
SPECIFIC AIM #4: To determine the effect of inhibiting PG production with 
indomethacin and NS-398 on TNF-a induced osteoclastogenesis 
The results of adding either a nonselective COX inhibitor (indomethacin) or a 
selective COX-2 inhibitor (NS-398) to the RAW 264.7 cell cultures were very similar. 
When either indomethacin (Indo, 1 ~) or NS-398 (0.1 J.1M) were added to the cells, 
there was either an increase or no change in osteoclast number. On day 3, RANKL + 
Indo (820±25 cells/well) showed a significant increase compared to RANKL alone 
(507±18 cells/well) (Table 4 and Figure 13). Similarly, on day 3, TNF-a + NS-398 
(4.3±0.3 cells/well) was significantly greater than TNF-a alone (1.3±0.9 cells/well) as 
was RANKL + TNF-a + NS-398 (343.3±13 cells/well) compared to RANKL + TNF-a 
(255±21 cells/well) (Table 5 and Figure 14). Neither of these inhibitors of PG 
production caused a decrease in the number ofMNCs formed, except on day 5. On day 
5, when treated with TNF-a + Indo as compared to TNF-a, the osteoclast number 
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decreased by a mean of 168 cells. Similarly, in the TNF-a + NS398 treatment group, 
there was a mean decrease of 63 in the number of osteoclasts as compared to TNF-a 
alone. With RANKL+TNF-a + NS 398, the osteoclast number decreased by 111 as 
compared to RANKL + TNF-a. However, none of these decreases were statistically 
significant. All other treatments, showed either a significant stimulatory effect or no 
change in osteoclast number when either indomethacin or NS-398 were added to the 
different treatments (Tables 4 and 5, Figures 13 and 14). 
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DISCUSSION 
Since RAW 264.7 cells do not make RANKL, the presence of TRAP stained 
MNCs in RAW 264.7 cells treated with 1NF-a indicates that 1NF-a alone can induce 
osteoclastogenesis by acting on the hematopoietic lineage. There was an increase in the 
number of TRAP stained mononuclear cells on day 3, and they appeared to aggregrate 
into clusters of cells. This could suggest the beginning of the transformation into 
osteoclasts, as multiple mononuclear cells fuse together to form MNCs (a key 
characteristic of osteoclasts). This observation is consistent with the recent studies of Li 
et al [29] and Yao et al [30] that concluded 1NF-a could increase the proliferation of 
osteoclast precursors in bone marrow by enhancing c-Fms (the receptor for M-CSF) 
expression in the osteoclast progenitor pool. These progenitors would then have a 
greater proliferative response to M-CSF. Hence, it would be interesting to quantify the 
cell numbers and examine the mRNA and protein expression of c-Fms in RA W 264.7 
cells treated with/without 1NF -a. It would also be interesting to examine the 
expression of M-CSF and the response to added M-CSF in cells treated with/without 
1NF-u. 
These authors (Li; Y ao) found that RANKL was necessary to produce mature 
multinucleated osteoclasts in their bone marrow culture system. On the other hand, 
consistent with our data, Zou et al [27] reported that 1NF-u alone can induce the 
formation of TRAP positive MNCs in RAW 264.7 cells. However, no RAW 264.7 data 
were actually shown in their paper, and there was no report of whether or not the TRAP 
positive ]vINCs formed in response to 1NF-u in RAW 264.7 cells could resorb bone. A 
recent article by Hotokezaka et al [31] suggests that 1NF -a alone can induce the fusion 
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of TRAP positive mononuclear cells (derived from RAW 264.7 cells) into TRAP 
positive MNCs through the TNF-a receptors. Subsequent activation of signaling 
pathways involving PI3K, Src, ERK and JNK molecules was required for the cell 
fusion. In the future we will need to demonstrate that our TRAP positive MNCs are 
truly mature osteoclasts by placing them on bone slices and showing that they can form 
pits. 
TNF -a was not as effective as RANKL in our model. The total number of TRAP 
positive MNCs formed after treatment with TNF-a was always lower than the number 
formed with RANKL alone in the same experiment. Similar results were found in the 
study by Azuma et al [1] where the number of TRAP-positive MNCs in TNF-a-treated 
groups was about 50% of that in the soluble RANKL-treated groups. Thus, it seems 
likely that under normal physiologic conditions, the RANKL pathway for 
osteoclastogenesis would predominate. Although we did demonstrate that a significant 
increase in the number of osteoclasts with RANKL + TNF-a as compared to RANKL 
alone, we must do more studies to determine whether this effect is additive or 
synergistic. Our previous experiments indicated 30 ng/m! ofRANKL produces maximal 
osteoclastogenesis in RAW 264.7 cells. Hence, the observation that TNF-a can increase 
the effects of 30 ng/ml RANKL on osteoclastogenesis suggests that the two agonists 
work in part by independent pathways. The decrease in osteoclast number seen on day 5 
with RANKL + TNF-a as compared to RANKL alone is possibly due to an acceleration 
of osteoclast formation, resulting in an earlier peak of osteoclast formation in the 
combination treatment, followed by normally occurring cell death, or perhaps by 
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increased apoptosis/cell death with the joint treatment. This could be studied by doing 
more precise time courses and using stains to demonstrate the apoptotic cells. 
One of the ways that TNF -a may enhance the effect of RANKL is to upregulate 
the RANK receptor. The combination of TNF-a and RANKL was found to 
synergistically upregulate RANK expression in osteoclast precursor cells isolated from 
marrow cultures by Zhang et al [32]. We can use leftover RNA extracted from our 
cultures to investigate this possibility in RAW 264.7 cells. These authors also found 
that that TNF -a enhanced RANKL induced osteoclastogenesis by interaction of the 
signaling pathways downstream from the RANK and ThTF -a receptor 1 and that these 
coupling effects were dependent on the TNF-a receptor 1. 
Although RAW 264.7 cells are not supposed to express RANKL, we considered 
the possibility that TNF-a could induce RANKL in these cells. We tried to measure 
RANKL mRNA by real time PCR but it was undetectable (data not shown). Other 
possible experiments to confirm that RANKL was not involved in the effects of TNF-a 
would be to see what happened to the effects ofTNF-a after treating cultures with OPG, 
knocking down receptors for TNF-a with small interfering RNAs, or using specific 
blocking antibodies for TNF-a. 
It is also possible that RANKL acts in part to increase osteoclastogenesis via 
induction ofTNF-a. For example, Nakao et al [33] have shown that RANKL stimulates 
TNF-a expression and that formation of TRAP positive MNCs in RAW 264.7 cultures 
were reduced by treatment with specific blocking antibodies to TNF-a or to TNF-a 
receptor 1. We address this issue by using RNA extracted from our cultures to measure 
TNF-a mRNA levels after treatment with/without RANKL +/- TNF-a. 
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We found increased PGE2 in the media collected from the wells treated with 
TNF -a. This suggests that TNF -a stimulates PGE2 production and is consistent with 
studies from Han et al [23]. These authors showed that RANKL transcriptionally 
upregulated COX-2 expression in RAW 264.7 cells but did not show effects of 
inhibiting COX-2 activity on osteoclast formation in these cells (only in bone marrow 
derived osteoclasts). In our studies, the medium PGE2 increased from day 2 to day 4, 
suggesting that the peak in PGE2 production coincided with the peak in osteoclast 
formation. However, in contrast to our original hypothesis, we found that inhibiting PG 
production with NSAIDs, NS-398 or indomethacin, did not decrease osteoclast 
formation in any of the treatment groups: RANKL, ll\JF-a, or the combination. In fact, 
in many cases, addition of NSAID significantly stimulated the formation of TRAP 
positive MNCs. 
We had expected that inhibiting PG production would decrease the effect of 
RANKL since it has been reported that RANKL-induced COX-2 expression and PG 
production are required for maximal effects of RANKL stimulated osteoclastic 
differentiation by Han et al [23]. However, these investigators only showed the effects 
of inhibiting COX-2 activity on RANKL-induced osteoclastogenesis in bone marrow 
derived osteoclast cultures and not in RAW 264.7 cells. It is likely that the bone 
marrow derived osteoclast cultures also contained some osteoblasts or stromal cells and 
perhaps the presence of these cells had some influence on the effects of the NSAIDs. 
PGs are known to increase osteoblast formation by recruiting osteoblast precursors from 
mesenchymal precursors in the bone marrow stromal cultures [24]. 
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There are other studies showing that PGs can inhibit osteoclast formation in 
cultures containing only cells of the hematopoietic lineage. For example, a recent 
article by Akaogi et al [34] showed that PGE2 could suppress osteoclastogenesis by 
inhibiting IL-17-induced TNF-a expression in macrophages. Ono et al [35] showed that 
PGE2 had biphasic effects on spleen cell cultures from mice. Spleen contains 
hematopoietic lineage cells but no osteoblast lineage cells and spleen cells can 
differentiate into osteoclasts if given RANKL and M-CSF. In these cells, PGE2 had an 
initial inhibitory effect on osteoclastogenesis, followed by a stimulatory effect. The 
stimulatory effect was postulated to be due to factors secreted by T cells in the spleen 
cultures. Take et al [36] have also reported that PGE2 inhibits osteoclast formation in 
cultures of cells prepared from human peripheral blood mononuclear cells (PBMCs). 
These cultures do not contain any osteoblasts or stromal cells and they were selected to 
contain no T cells as well. They also found that NS-398 enhanced osteoclast formation 
when these PBMCs were co-cultured with a clonal osteoblast cell line isolated from an 
osteosarcoma. It is possible that PGs have different effects on different stages of the 
hematopoietic lineage or that effects will vary depending on other cells in the 
environment. 
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SIGNIFICANCE OF THE RESULTS 
This study will give us a better understanding of the role of TNF -(1 in 
osteoclastogenesis and bone remodeling and its mechanism of action via COX-2 and 
prostaglandin production. This is turn will help us better understand the therapeutic 
ability of nonselective NSAIDS and selective COX-2 inhibitors. It will shed some light 
on the causes of several metabolic bone diseases caused by abnormal osteoclast 
recruitment and functions such as osteopetrosis, osteoporosis, metastatic bone disease, 
Paget's disease, rheumatoid arthritis and periodontal disease [10]. In addition, it will 
give orthodontists greater insight into the mechanisms involved in stimulation and 
inhibition of tooth movement. This in turn could improve the quality and efficiency of 
treatment. 
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TABLES 
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TREATMENTS DAY 2 DAY 3 DAY 4 
Control ND ND ND 
+ Indo ND ND ND 
TNF-a 17.8 59.2 78.6 
+Indo ND ND ND 
Table 1: PGE2 producti.on (pg/ml) on days 2, 3 and 4 measured by 
Cayman EIA. RAW 264.7 cells were treated with vehicle (Control) and 
TNF- a (10 ng/ml). Cultures were also treated with / without indomethacin 
(1 J1M), a nonselective inhibitor of both COX-1 and COX-2 activity. 
Units: pg/ml, Detection Range: 7.8 to 1000 pg/ml, ND non detectable 
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Groups Day 2 Day 3 Day 4 
Control ND 20.9 ND 
+Indo ND 23.0 26.9 
TNF-a 68.2 105.7 120.0 
+Indo 20.9 39.4 38.7 
Table 2: PGE2 production (pg/ml) on days 2, 3 and 4 measured by 
Cayman Express. RAW 264.7 cells were treated with vehicle (Control) 
and TNF-a (10 nglml). Cultures were also treated with / without 
indomethacin (1 flM), a nonselective inhibitor of both COX-I and COX-2 
activity. 
Units: pglml, Detection Range: 15.6 to 2000 pg/ml, ND non detectable 
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GrOUI!S Day 2 Day 3 Day 4 
Control ND ND ND 
+Indo ND ND ND 
TNF-a 77.85 336.2 439.6 
+Indo ND ND ND 
Table 3: PGEz production (pg/ml) on days 2, 3 and 4 measured by 
Assay Design EIA Kit. RAW 264.7 cells were treated with vehicle 
(Control) and TNF-a (10 ng/mI). Cultures were also treated with! without 
indomethacin (l ~), a nonselective inhibitor of both COX-l and COX-2 
activity. 
Units: pg/ml, Detection Range: 38.7 to 2600 pg/ml, ND - non detectable 
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TREATMENTS DAY 3 i DAY 4 DAYS 
Control 0 0 0 
+Indo 0 0 0 
TNF-a 4.7± 0.9 189.3 ± 4.9 462.3±33.0 
+Indo 11 0.7 240.7 ± 0.7 294.7±13.0 
RANKL 507.3± 17.8 949.0 ± 95.6 916.0±40.5 
+Indo 820.0± 25.1 a 1130.3±60.8 986.0±7S.l 
RANKL+ TNF-a 1370.7 ± 5.2 1606.7±45.3 769.3±20.2 
+Indo 1440.3±102.2 ''''''.0±74.8 737.7±13.6 
Table 4: Effect of Indomethacin on osteoclast formation. RAW 264.7 
cells were treated with vehicle (Control), TNF- u (10 ng/ml), RANKL (30 
ng/ml) , or the combination of RANKL + TNF- u. Cultures were also 
treated with / without indomethacin (1 ~), a nonselective inhibitor of 
both COX-l and COX-2 activity. Numbers are means ± SEM for n 3 wells 
of cells. 
aSignificant stimulatory effect of indomethacin, p <0.01. 
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DAY 3 DAY 4 DAYS 
Control 0 0 0 
+ NS398 0 0 0 
TNF-a 1.3 ± 0.9 53.7 ± 6.4 . ±18.6 
+ NS398 4.3 ± O.3a 62.3 ± 3.2 189.3±15.0 
RANKL 110.3 13.8 897.7 ± 79.8 843.3±31,4 
+ NS398 150.7 ± 14.4 1140.7±93.1 867.3±24.9 
RANKL +TNF-a 21.4 1429.3±93.0 636.0±52.1 
+ NS398 343.3 2.8a 1420.0±124.2 525.7±39.5 
Table 5: Effect of NS398 on osteoclast formation. RAW 264.7 cells were 
treated with vehicle (Control), TNF- a (10 ng/ml), RANKL (30 ng/ml), or 
the combination of RANKL + TNF- a. Cultures were also treated with / 
without NS398 (0.1 11M), a selective COX-2 inhibitor. Numbers are means 
± SEM for n=3 wells of cells. 
aSignificant stimulatory effect of indomethacin, p <0.05. 
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Figure 1: Osteoclast differentiation pathway (taken/rom Feng, X, 
2005 [9]), 
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production of prostaglandins (taken from Chapter 54 in Principles 
of Bone Biology by Pilbeam CC et al. [21 D. 
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37 
500 
a a 
400 
...... 
...... 
Q) 
~ 300 
---CZl 
U 
~ 200 
+ A-I 
~ 
E-- 100 
o 
Control PGE2 
(1 IlM) 
0.1 1 10 
TNF-a 
(ng/ml) 
Figure 4: Effects of TNF -(1 and PGE2 on osteoclastogenesis in 
RAW 264.7 cells treated with 30 ng/ml RANKL. Cells were 
cultured for 5 days in the presence of RANKL plus treatments as 
indicated. There was a significant increase in TRAP positive 
multinucleated cells (MNCs) when the cells were treated with 
PGEz (1 ~) or with TNF-a (1 and 10 ng/ml). 
aSignificantly different from control, P< 0.01; 
bSignificantly different from control, P< 0.05 
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Figure 5: Effects of inhibiting PGE2 production by 
NS-398 (0.1 ~) on TNF -ex induced osteocIastogenesis 
in RAW 264.7 cells treated with 30 ng/ml RANKL. 
Cells were treated for 5 days. NS-398, a selective COX-2 
inhibitor, inhibited the induction of TRAP positive 
multinucleated cells (MNCs) stimulated by PGE2 and 
TNF-a. 
aSignificantly different from control, P< 0.01 
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Figure 6: TRAP staining following treatment with 
RANKL (30 ng/ml), TNF-u (10 nglml) or RANKL + TNF-
u. Cells were treated for the number of days indicated and 
stained with TRAP. Dishes were scanned into Adobe 
Photoshop. TRAP positive cells appear pink/purple. With 
both RANKL and RANKL + TNF -(1, there was an increase 
in TRAP positive cells on days 3 and 4. Although not 
apparent in this picture, "ghost cells" (structures that appear 
to be dead TRAP positive cells) appeared on day 5. With 
TNF -(1 alone, TRAP positive cells are visible on day 5. 
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Figure 7: Microscopic images of osteoclast formation 
following treatment with TNF -u (10 ng/ml), RANKL (30 
ng/ml) or RANKL + TNF -u. Mononuclear cells increased 
in number in cultures treated with TNF -u alone on day 3 and 
TRAP positive NINCs appeared on days 4 and 5. The 
combination of RANKL + TNF -u increased the number of 
TRAP positive NINCs, compared to RANKL alone, on days 
3 and 4. Ghost cells appeared on day 5 in RANKL treatment 
groups. 
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Figure 8: Quantification of TRAP positive MNCs on 
days 3, 4 and 5 in RAW 264.7 cell cultures treated with 
TNF-a (10 ng/ml) alone. 
aSignificantly different from control, p<O.Ol. 
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Figure 9: Quantification of TRAP positive MNCs on 
days 3, 4 and 5 in RAW 264.7 cell cultures treated 
with TNF -(1 (10 ng/ml) alone. 
aSignificantly different from control, p<O.O 1. 
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Figure 10: Quantification of TRAP positive MNCs on 
days 3, 4 and 5 in RAW 264.7 cell cultures treated with 
TNF-a (10 ng/ml) alone. In some experiments TRAP 
positive MNC number peaked later than day 4. 
aSignificantly different from control, p<O.Ol. 
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Figure 11: Effect of TNF -a (10 ng/ml) on RANKL-
induced osteoclastogenesis in RAW 264.7 cells on 
days 3, 4 and 5. On days 3 and 4 of cell culture, there 
were a significantly greater number of TRAP positive 
MNCs formed with RANKL+ TNF-a compared to 
RANKL alone. 
aSignificantly different from control, P< 0.01 
bSignificantly different from control, P< 0.05 
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Figure 12: Effect ofTNF-a (10 ng/ml) on 
the induction of COX-2 mRNA expression 
on day 3 of cell culture. 
Bars are means ± SEM for 3 samples. 
aSignificantly different from control, p <0.01 
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Figure 13: Effect of Indomethacin on osteoclastogenesis 
in RAW 264.7 cells 
Bars are means ± SEM for 3 samples. 
aSignificant stimulatory effect of indomethacin, p <0.01 
bSignificant stimulatory effect of indomethacin, p <0.05 
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Figure 14: Effect of NS 398 on osteoclastogenesis 
in RAW 264.7 cells Bars are means ± SEM for 3 
samples. 
aSignificant stimulatory effect of NS 398, P <0.01 
bSignificant stimulatory effect of NS 398, P <0.05 
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